Immunology Investor Event
sanofi
Next-generation of oral pathway medicines
soluble
TNFα
TNFα Inh
YYY
IL-17A
Y
IL-17A Blocker
IL1/IL18/IL33/IL36
Y Y
Y Y
Antibody-like efficacy with oral
convenience
Soluble TNFα Inhibitor (SAR441566)
selectively blocks TNFR1 signaling
Oral IL-17A Blocker target a key
pro-inflammatory pathway
TNFR1 INF-R TLR4
IL-17R
BCR FcR
TLRS IL-XR
RIPK1
RIPK1 Inh
BTK Inh
BTK
IRAK4
IRAK4 Inh
Tissue Inflammation
Dermatology | Respiratory | Gastroenterology | Rheumatology
48 Immunology Investor Event
Tackling nodal targets
RIPK1 Inhibitor (eclitasertib) targets
a master regulator of cell death and
proinflammatory cytokine production
BTK Inhibitor covalent reversible
(rilzabrutinib) targets 2 key molecular
pathways
IRAK4 Degrader - blockade of kinase
and scaffold function for maximal
disease impactView entire presentation